Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg

Showing results (301-310 of 333) with videos related to

Pageof 34
Sort By:
Gut|January 10, 2024
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver diseaseAngelo Armandi, Tiziana Sanavia, Ramy Younes, et al.
Nature Reviews. Gastroenterology & Hepatology|October 28, 2021
Advancing the global public health agenda for NAFLD: a consensus statementJeffrey V Lazarus, Henry E Mark, Quentin M Anstee, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Zeitschrift Fur Gastroenterologie|December 9, 2025
Clinical characteristics of newly diagnosed patients with primary biliary cholangitis (PBC) indicate the need for better awareness on timely diagnosis and adequate UDCA therapyKerstin Stein, Wolf P Hofmann, Annegret Franke, et al.
Zeitschrift Fur Gastroenterologie|September 3, 2024
Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohortJohannes Wiegand, Annegret Franke, Tobias Müller, et al.
Med (New York, N.Y.)|April 7, 2026
Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysisTsubasa Tsutsumi, Nicole Shu Ying Tang, Cheng Han Ng, et al.
Annals of Hepatology|October 13, 2025
Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary careToni Herta, Annegret Franke, Tobias Müller, et al.
The Lancet Regional Health. Europe|June 10, 2026
Assessing Europe's policy readiness to confront the MASLD/MASH public health threatJeffrey V Lazarus, Trenton M White, Leire Agirre-Garrido, et al.
Hepatology (Baltimore, Md.)|March 30, 2023
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation studyJenny Lee, Max Westphal, Yasaman Vali, et al.
Hepatology (Baltimore, Md.)|March 16, 2023
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetesGrazia Pennisi, Marco Enea, Vincenzo Falco, et al.
Pageof 34

Showing results (301-310 of 333) with videos related to

Sort By:
Pageof 34
Gut|January 10, 2024
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver diseaseAngelo Armandi, Tiziana Sanavia, Ramy Younes, et al.
Nature Reviews. Gastroenterology & Hepatology|October 28, 2021
Advancing the global public health agenda for NAFLD: a consensus statementJeffrey V Lazarus, Henry E Mark, Quentin M Anstee, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Zeitschrift Fur Gastroenterologie|December 9, 2025
Clinical characteristics of newly diagnosed patients with primary biliary cholangitis (PBC) indicate the need for better awareness on timely diagnosis and adequate UDCA therapyKerstin Stein, Wolf P Hofmann, Annegret Franke, et al.
Zeitschrift Fur Gastroenterologie|September 3, 2024
Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohortJohannes Wiegand, Annegret Franke, Tobias Müller, et al.
Med (New York, N.Y.)|April 7, 2026
Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysisTsubasa Tsutsumi, Nicole Shu Ying Tang, Cheng Han Ng, et al.
Annals of Hepatology|October 13, 2025
Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary careToni Herta, Annegret Franke, Tobias Müller, et al.
The Lancet Regional Health. Europe|June 10, 2026
Assessing Europe's policy readiness to confront the MASLD/MASH public health threatJeffrey V Lazarus, Trenton M White, Leire Agirre-Garrido, et al.
Hepatology (Baltimore, Md.)|March 30, 2023
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation studyJenny Lee, Max Westphal, Yasaman Vali, et al.
Hepatology (Baltimore, Md.)|March 16, 2023
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetesGrazia Pennisi, Marco Enea, Vincenzo Falco, et al.
Pageof 34